Zenagamtide phase 2 results: 14.6% weight loss and what it means

Every year the bar moves. Semaglutide delivered 15% weight loss at 68 weeks and changed medicine. Tirzepatide followed with 22.5% at 72 weeks and moved it further. Now Novo Nordisk has presented Phase 2 data for zenagamtide - also known as amycretin - at the ADA 2026 Scientific Sessions, and the results suggest a drug that works through a different mechanism to both, with 14.6% weight loss in type 2 diabetes patients at just 36 weeks and no sign of a plateau. What it means for people on GLP-1 medications today is worth understanding clearly.

TL;DR

Zenagamtide is Novo Nordisk's first-in-class drug combining GLP-1 and amylin receptor agonism in a single molecule. Phase 2 data from ADA 2026 showed 14.6% weight loss and A1C reduction of 1.71 percentage points at 36 weeks in T2D patients, with no weight loss plateau observed. Phase 3 in T2D is planned for H2 2026; widespread availability is likely 2028 at the earliest.

What zenagamtide is and why it is different

Existing GLP-1 medications - semaglutide and liraglutide - work through a single receptor: the GLP-1 receptor, which governs appetite, gastric emptying, and insulin secretion. Tirzepatide added a second receptor, GIP, creating a dual mechanism that explains its superior weight loss numbers over semaglutide.

Zenagamtide takes a different second mechanism. Rather than combining GLP-1 with GIP, it combines GLP-1 with amylin. Amylin is a hormone secreted alongside insulin by pancreatic beta cells. It regulates gastric emptying, satiety signals to the brain, and glucagon secretion after meals. People with type 2 diabetes often have impaired amylin secretion alongside impaired insulin secretion - so replacing both signals together is a logical therapeutic target.

Amylin receptor agonism has been explored before. Pramlintide (Symlin) was approved as an amylin mimetic, but its short half-life required multiple daily injections and it never gained widespread use. Zenagamtide solves this by packaging GLP-1 and amylin agonism in a single weekly injection - the same dosing convenience as semaglutide.

The Phase 2 trial design and results

The trial enrolled 262 adults with type 2 diabetes who had A1C between 7.0-10.0% and were on stable metformin, with or without an SGLT2 inhibitor. Participants were randomised to one of six doses of zenagamtide (0.4 mg through 40 mg) or placebo and treated for 36 weeks. Mean baseline weight was around 99 kg (219 lbs).

The primary endpoint was A1C reduction, and zenagamtide delivered dose-dependent results at all six doses. At the highest dose (40 mg):

• A1C fell by 1.71 percentage points versus 0.14 in the placebo group - a 1.56 percentage point treatment difference (p<0.0001)
• 89.1% of participants achieved A1C below 7%
• 76.2% achieved A1C at or below 6.5%
• Time in blood glucose target range (70-180 mg/dL) reached 91.5%

The weight loss data was the headline finding at ADA 2026. At 40 mg, participants lost 14.6% of body weight versus 2.1% in the placebo group - starting from a baseline of approximately 99 kg, that translates to roughly 14.5 kg (32 lbs) of weight loss at 36 weeks in a type 2 diabetes population. The dose-response was consistent: even the lowest dose (0.4 mg) produced 4.35% weight loss, and each step up in dose produced further loss.

The no-plateau finding

The detail that generated the most discussion at ADA 2026 was this: no apparent weight loss plateau was observed at 36 weeks with higher doses. Most GLP-1 weight loss trials plateau somewhere between week 52 and week 68 - the point at which the body's compensatory hunger signalling catches up to the drug's appetite suppression. The Phase 2 zenagamtide data shows a continued downward trajectory at week 36 with no sign of levelling off.

This could reflect several things. The amylin mechanism may complement GLP-1's appetite suppression through a different satiety pathway, delaying or preventing the plateau that single-pathway drugs encounter. Alternatively, a 36-week study window may simply not be long enough to observe a plateau for this drug. Phase 3 data at 52-68 weeks will answer that question. But if the non-plateauing effect holds, zenagamtide could deliver meaningfully higher total weight loss than current options across longer treatment periods.

Safety and tolerability

Gastrointestinal side effects were the most common adverse events, consistent with other incretin and amylin-based therapies. The severity was characterised as "majority mild to moderate," with no new safety signals that would restrict Phase 3 development. The safety profile is important context: the addition of amylin agonism did not appear to worsen tolerability relative to GLP-1 drugs alone.

Martin Holst Lange, Chief Scientific Officer and EVP R&D at Novo Nordisk, described the results as building "on growing evidence of potential to meaningfully impact blood glucose and body weight." Novo Nordisk plans Phase 3 development initiation in H2 2026, with separate programmes investigating both oral and subcutaneous administration routes.

How zenagamtide compares to existing options

A direct head-to-head comparison with semaglutide or tirzepatide has not yet been conducted. The Phase 2 data cannot be compared directly to Phase 3 data from other drugs due to different patient populations, trial durations, and study designs. What can be said:

• 14.6% weight loss at 36 weeks in a T2D population is numerically competitive with Wegovy's 15% at 68 weeks in non-diabetic patients
• A1C reduction of 1.71% is within the range of semaglutide and tirzepatide in T2D trials
• The combination mechanism is genuinely different from tirzepatide's GLP-1/GIP approach
• The no-plateau signal at 36 weeks differentiates it from the plateau observed in semaglutide trials at similar timepoints

Whether zenagamtide is better, worse, or equivalent to current options will not be known until Phase 3 data is available - and even then, the practical question of which drug works best for which patient will take longer to resolve.

When will zenagamtide be available?

Phase 3 is planned for H2 2026 in type 2 diabetes. Assuming a 2-3 year Phase 3 trial and a standard regulatory review, a realistic timeline for potential FDA approval is 2028-2029. Obesity indication development would follow the diabetes programme, pushing that approval further. For people on GLP-1 medications today, zenagamtide is not a near-term option - it is an evolving pipeline candidate whose Phase 3 data will shape the treatment landscape of the late 2020s.

What this means for current GLP-1 users

If you are on Ozempic, Wegovy, Mounjaro, or Zepbound, zenagamtide is not something you need to act on today. What the Phase 2 data does establish is that the GLP-1 drug class continues to evolve rapidly, with new combinations and mechanisms consistently delivering improved outcomes. The practical implication for current users:

• Your current medication is supported by substantial Phase 3 evidence - you are not behind the science by being on semaglutide or tirzepatide
• The treatment landscape will look different in 2028-2030; if your current drug is not delivering the outcomes you need, options will expand
• Regardless of which drug you take, the nutritional gaps created by reduced food intake remain consistent across the drug class - addressing them now matters regardless of future treatment changes

Protecting your nutritional baseline across drug transitions

Every GLP-1 and GLP-1-like drug works by reducing how much you eat. The nutritional consequence is the same across molecules: vitamin B12, vitamin D, magnesium, iron, and protein intake all fall when total food consumption drops by 30-40%. These deficiencies develop on a months-long timeline and are often asymptomatic until they cause measurable harm - fatigue, muscle loss, bone weakening, or mood changes.

GLP-1 Shield is designed around these specific gaps, providing the nutrients that GLP-1 medications predictably deplete regardless of which generation of drug you take. Building a solid nutritional foundation now means your body is in better shape to benefit from both current medications and whatever improvements the next generation of drugs delivers.

Frequently asked questions

What is zenagamtide and how is it different from Ozempic?

Zenagamtide (also called amycretin) is a single molecule that activates both GLP-1 receptors and amylin receptors simultaneously. Ozempic (semaglutide) acts only on GLP-1 receptors. The addition of amylin agonism adds a second satiety mechanism - the same hormone that is co-secreted with insulin by the pancreas. Phase 2 data shows 14.6% weight loss at 36 weeks with no plateau observed at that point.

Is zenagamtide available now?

No. Zenagamtide is in Phase 2 clinical development for type 2 diabetes. Phase 3 trials are planned to begin in H2 2026. A realistic timeline for potential FDA approval, assuming successful Phase 3 results, is 2028-2029 for the diabetes indication. Obesity indication approval would follow later.

Why did the ADA 2026 data show no weight loss plateau?

Most GLP-1 weight loss trials show a plateau between weeks 52-68 when the body's compensatory hunger mechanisms partially overcome the drug's appetite suppression. Zenagamtide's amylin receptor mechanism adds a second satiety pathway that may delay or prevent this plateau. However, the Phase 2 trial only ran 36 weeks - Phase 3 will determine whether the non-plateauing effect holds at longer timepoints.

Should I switch from Ozempic or Wegovy to zenagamtide?

Zenagamtide is not available outside clinical trials. When it does become available, the decision to switch would depend on Phase 3 efficacy and safety data, individual response to current therapy, and prescribing guidelines that do not yet exist. For most current GLP-1 users, the better focus right now is optimising outcomes on their current medication through adequate protein intake, resistance exercise, and nutritional support.